Amber Therapeutics occupies a distinctive niche as the only implantable neuromodulation company specifically targeting mixed urinary incontinence via pudendal nerve stimulation, a condition underserved by existing sacral neuromodulation devices. Its landmark $100M Series A in 2024 signals significant investor conviction, though the company remains pre-approval and faces the clinical and regulatory burden typical of novel implantable indications.